JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1984; 4:111-116
© 1984 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nademanee, K
Right arrow Articles by Singh, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nademanee, K
Right arrow Articles by Singh, B.

Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications

K Nademanee, R Kannan, J Hendrickson, M Ookhtens, I Kay, and BN Singh

Administration of amiodarone (600 to 1,600 mg/day) to 28 patients during long-term digoxin therapy (0.25 +/- 0.05 mg/day) increased serum digoxin level from 0.97 +/- 0.45 to 1.98 +/- 0.84 ng/ml (p less than 0.001). Gastrointestinal side effects occurred in nine patients, central nervous system reactions occurred in five and cardiovascular reactions occurred in four. Pharmacokinetic studies in six patients with a 1 mg intravenous digoxin dose before and during amiodarone therapy increased serum digoxin level at 30 minutes from 8.59 +/- 1.68 to 10.07 +/- 1.70 ng/ml (p less than 0.05). Amiodarone caused a 31% prolongation of digoxin elimination half-life from 49.5 +/- 8.8 to 65.0 +/- 28.8 hours, but the increase in half-life was not statistically significant. Total body clearance was reduced significantly (29%, p less than 0.05) from 2.05 +/- 0.76 to 1.46 +/- 0.64 ml/min per kg. Nonrenal clearance also showed a significant decrease (33%, p less than 0.05) from 1.20 +/- 0.46 to 0.80 +/- 0.30 ml/min per kg. The renal clearance decreased by 22% and the volume of distribution decreased by 11% after amiodarone therapy, but these changes were not significant. The data show that the mechanism of digoxin-amiodarone interaction is multifactorial and emphasize the need for close monitoring of serum digoxin levels and clinical features during concurrent digoxin-amiodarone therapy.


This article has been cited by other articles:


Home page
 JAMAHome page
S. de Denus and S. A. Spinler
Optimal Digoxin Concentrations for Patients With Heart Failure
JAMA, May 28, 2003; 289(20): 2643 - 2643.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. Tanaka, K. Matsumoto, K. Ueno, M. Kodama, K. Yoneda, Y. Katayama, and K. Miyatake
Effect of Clarithromycin on Steady-State Digoxin Concentrations
Ann. Pharmacother., February 1, 2003; 37(2): 178 - 181.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. F. Fromm, R. B. Kim, C. M. Stein, G. R. Wilkinson, and D. M. Roden
Inhibition of P-Glycoprotein–Mediated Drug Transport : A Unifying Mechanism to Explain the Interaction Between Digoxin and Quinidine
Circulation, February 2, 1999; 99(4): 552 - 557.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
Y.-G. Li and S. H. Hohnloser
Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 185 - 194.
[Abstract] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1984 by the American College of Cardiology Foundation.